Systematic review shows rapid diagnostic tests offer faster, cheaper HIV detection for LAI-PrEP users with low certainty evidence.
Rapid tests find HIV just as well as lab tests but cost less and work faster.
This systematic review and meta-analysis evaluated HIV detection strategies, including rapid diagnostic tests (RDTs), laboratory-based immun…
For people on long-acting HIV prevention, rapid tests match lab accuracy while cutting costs and speeding up treatment starts.
Cochrane review: injectable lenacapavir cuts HIV infections versus oral PrEP at 52 weeks
One Shot Saves You From HIV For Six Months
This Cochrane systematic review and meta-analysis of two randomised controlled trials (8660 participants) compared six-monthly subcutaneous …
A single shot under the skin protects against HIV for six months, solving the daily pill problem for millions at risk.
Injectable lenacapavir receives clinical recommendation for HIV preexposure prophylaxis in US
New HIV prevention shot gets official recommendation. What does that mean?
A clinical recommendation supports the use of injectable lenacapavir for HIV preexposure prophylaxis in the United States. Key study details…
Health experts now officially recommend an injectable shot as a new option for people at risk to prevent getting HIV.
Bictegravir-lenacapavir single-tablet regimen non-inferior to complex regimens for HIV-1 suppression at 48 weeks
Can a single daily pill control HIV as well as complex multi-pill regimens?
In this phase 3 randomized trial of 557 virologically suppressed adults with HIV-1 on complex regimens, switching to once-daily oral bictegr…
A new single daily pill kept HIV suppressed just as well as complex multi-pill regimens in a trial of 557 adults who had been on treatment f…